| Year |
Citation |
Score |
| 2023 |
Ashoorzadeh A, Mowday AM, Abbattista MR, Guise CP, Bull MR, Silva S, Patterson AV, Smaill JB. Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506. Acs Medicinal Chemistry Letters. 14: 1517-1523. PMID 37974941 DOI: 10.1021/acsmedchemlett.3c00321 |
0.345 |
|
| 2022 |
Ashoorzadeh A, Mowday AM, Guise CP, Silva S, Bull MR, Abbattista MR, Copp JN, Williams EM, Ackerley DF, Patterson AV, Smaill JB. Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications. Pharmaceuticals (Basel, Switzerland). 15. PMID 35215297 DOI: 10.3390/ph15020185 |
0.419 |
|
| 2021 |
Singleton DC, Mowday AM, Guise CP, Syddall SP, Bai SY, Li D, Ashoorzadeh A, Smaill JB, Wilson WR, Patterson AV. Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411 leading to therapeutic benefit. Cancer Gene Therapy. PMID 34837065 DOI: 10.1038/s41417-021-00409-2 |
0.578 |
|
| 2021 |
Fu Z, Mowday AM, Smaill JB, Hermans IF, Patterson AV. Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy. Cells. 10. PMID 33923305 DOI: 10.3390/cells10051006 |
0.516 |
|
| 2021 |
Mowday AM, Dubois LJ, Kubiak AM, Chan-Hyams JVE, Guise CP, Ashoorzadeh A, Lambin P, Ackerley DF, Smaill JB, Minton NP, Theys J, Patterson AV. Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours. Cancer Gene Therapy. PMID 33558701 DOI: 10.1038/s41417-021-00296-7 |
0.475 |
|
| 2020 |
Mowday AM, Copp JN, Syddall SP, Dubois LJ, Wang J, Lieuwes NG, Biemans R, Ashoorzadeh A, Abbattista MR, Williams EM, Guise CP, Lambin P, Ackerley DF, Smaill JB, Theys J, ... Patterson AV, et al. nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications. Theranostics. 10: 10548-10562. PMID 32929365 DOI: 10.7150/Thno.46826 |
0.316 |
|
| 2019 |
Williams EM, Rich MH, Mowday AM, Ashoorzadeh A, Copp JN, Guise CP, Anderson RF, Flanagan JU, Smaill JB, Patterson AV, Ackerley DF. Engineering NfsB to activate a hypoxia-resistant analog of the PET probe EF5 to enable non-invasive imaging during enzyme-prodrug therapy. Biochemistry. PMID 31403283 DOI: 10.1021/acs.biochem.9b00376 |
0.374 |
|
| 2018 |
Chan-Hyams JVE, Copp JN, Smaill JB, Patterson AV, Ackerley DF. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy. Biochemical Pharmacology. PMID 30352235 DOI: 10.1016/j.bcp.2018.10.020 |
0.428 |
|
| 2017 |
Copp JN, Mowday AM, Williams EM, Guise CP, Ashoorzadeh A, Sharrock AV, Flanagan JU, Smaill JB, Patterson AV, Ackerley DF. Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy. Cell Chemical Biology. PMID 28262557 DOI: 10.1016/j.chembiol.2017.02.005 |
0.417 |
|
| 2016 |
Mowday AM, Ashoorzadeh A, Williams EM, Copp JN, Silva S, Bull MR, Abbattista MR, Anderson RF, Flanagan JU, Guise CP, Ackerley DF, Smaill JB, Patterson AV. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy. Biochemical Pharmacology. PMID 27453434 DOI: 10.1016/j.bcp.2016.07.015 |
0.433 |
|
| 2016 |
Mowday AM, Guise CP, Ackerley DF, Minton NP, Lambin P, Dubois LJ, Theys J, Smaill JB, Patterson AV. Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress. Cancers. 8. PMID 27367731 DOI: 10.3390/Cancers8070063 |
0.419 |
|
| 2015 |
Williams EM, Little RF, Mowday AM, Rich MH, Chan-Hyams JV, Copp JN, Smaill JB, Patterson AV, Ackerley DF. Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility. The Biochemical Journal. 471: 131-53. PMID 26431849 DOI: 10.1042/BJ20150650 |
0.459 |
|
| 2013 |
Green LK, Storey MA, Williams EM, Patterson AV, Smaill JB, Copp JN, Ackerley DF. The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy. Cancers. 5: 985-97. PMID 24202330 DOI: 10.3390/cancers5030985 |
0.445 |
|
| 2013 |
Su J, Gu Y, Pruijn FB, Smaill JB, Patterson AV, Guise CP, Wilson WR. Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence. The Journal of Biological Chemistry. 288: 37138-53. PMID 24196959 DOI: 10.1074/jbc.M113.505222 |
0.341 |
|
| 2013 |
Green LK, Syddall SP, Carlin KM, Bell GD, Guise CP, Mowday AM, Hay MP, Smaill JB, Patterson AV, Ackerley DF. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy. Molecular Cancer. 12: 58. PMID 23758947 DOI: 10.1186/1476-4598-12-58 |
0.404 |
|
| 2013 |
Prosser GA, Copp JN, Mowday AM, Guise CP, Syddall SP, Williams EM, Horvat CN, Swe PM, Ashoorzadeh A, Denny WA, Smaill JB, Patterson AV, Ackerley DF. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A. Biochemical Pharmacology. 85: 1091-103. PMID 23399641 DOI: 10.1016/j.bcp.2013.01.029 |
0.352 |
|
| 2012 |
Michaelsen SR, Christensen CL, Sehested M, Cramer F, Poulsen TT, Patterson AV, Poulsen HS. Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells Journal of Gene Medicine. 14: 445-458. PMID 22576955 DOI: 10.1002/jgm.2630 |
0.392 |
|
| 2012 |
Hunt MA, Li D, Hay MP, Currie MJ, Robinson BA, Patterson AV, Dachs GU. Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro. The Journal of Gene Medicine. 14: 62-74. PMID 22147660 DOI: 10.1002/jgm.1635 |
0.411 |
|
| 2010 |
Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Research. 70: 1573-84. PMID 20145130 DOI: 10.1158/0008-5472.CAN-09-3237 |
0.448 |
|
| 2009 |
Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules (Basel, Switzerland). 14: 4517-45. PMID 19924084 DOI: 10.3390/molecules14114517 |
0.576 |
|
| 2008 |
Liu SC, Ahn GO, Kioi M, Dorie MJ, Patterson AV, Brown JM. Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. Cancer Research. 68: 7995-8003. PMID 18829557 DOI: 10.1158/0008-5472.CAN-08-1698 |
0.377 |
|
| 2007 |
Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang S, Denny WA, Wilson WR. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3922-32. PMID 17606726 DOI: 10.1158/1078-0432.CCR-07-0478 |
0.304 |
|
| 2005 |
Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, Williams KJ, Patterson AV, Stratford IJ, Morrow CS, Townsend AJ, Jounaidi Y, Chen CS, Su T, Lu H, Schwartz PS, et al. Cancer chemotherapy and drug metabolism. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 1083-96. PMID 16049130 DOI: 10.1124/Dmd.105.004374 |
0.337 |
|
| 2003 |
Cowen RL, Patterson AV, Telfer BA, Airley RE, Hobbs S, Phillips RM, Jaffar M, Stratford IJ, Williams KJ. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. Molecular Cancer Therapeutics. 2: 901-9. PMID 14555709 |
0.373 |
|
| 2003 |
Patterson AV, Saunders MP, Greco O. Prodrugs in genetic chemoradiotherapy. Current Pharmaceutical Design. 9: 2131-54. PMID 14529410 DOI: 10.2174/1381612033454117 |
0.631 |
|
| 2002 |
McNally VA, Patterson AV, Williams KJ, Cowen RL, Stratford IJ, Jaffar M. Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours. Current Pharmaceutical Design. 8: 1319-33. PMID 12052210 DOI: 10.2174/1381612023394548 |
0.42 |
|
| Show low-probability matches. |